Razelle Kurzrock: What’s old is new again

Razelle Kurzrock shared a post on X:

“What’s old is new again!!

Her2 expression across cancers If it’s a target, it’s a pan-cancer target: tissue is not the issue.

Our clinical experience is that Enhertu is a great drug.

Perhaps better tolerated and still very active at 2.7 mg/kg Iv q3 wks rather than 5.4 mg/kg)”

Tittle: HER2 aberrations in cancer: implications for therapy

Authors: Min Yan, Barbara A Parker, Richard Schwab and Razelle Kurzrock

Source:Razelle Kurzrock/X

Dr. Razelle Kurzrock is the Chief Medical Officer at ACT Genomics, Senior Deputy Director at the HKSH Cancer Centre, and Senior Advisor at CureScience. She is also a Professor of Medicine at the University of California, San Diego (UCSD) and the Director of the Center for Personalized Cancer Therapy at UCSD. Additionally, Dr. Kurzrock is the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center. Renowned as one of the world’s top 25 voices in precision medicine, she is celebrated for her contributions, of having over 950 scientific and medical publications.